Literature DB >> 24507404

Coronary artery bypass in patients with type 2 diabetes: experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Edward Y Sako1, Maria Mori Brooks2, Regina M Hardison2, Hartzel Schaff3, Robert L Frye3.   

Abstract

OBJECTIVE: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) was a study of management strategies for diabetic patients with myocardial ischemia and coronary artery disease. In a 2×2 design, early revascularization versus medical management with or without late revascularization and insulin sensitization versus insulin provision were examined. No advantage for either strategy was seen, except in the group undergoing early coronary artery bypass grafting (CABG). In that group, a reduction in subsequent myocardial infarction was noted. The purpose of our report was to characterize the conduct and short-term outcomes for CABG that led to this result.
METHODS: Data from the BARI 2D CABG stratum were collected, including the baseline demographic and cardiovascular characteristics, technical details of the operation, and perioperative morbidity and mortality, and analyzed.
RESULTS: A total of 347 patients were studied. The average cardiac function was normal, and most had multivessel disease. Almost all had undergone CABG by way of a median sternotomy using an internal mammary artery, and one third were off pump. The perioperative morbidity and mortality were low and compared well with larger outcomes databases.
CONCLUSIONS: BARI 2D showed that early CABG in patients with type 2 diabetes and myocardial ischemia and multivessel disease reduced the subsequent myocardial infarction rates. The present results have demonstrated that this was achieved using off-pump surgery in certain cases, standard myocardial protection, and routine use of the internal mammary artery or other arterial grafts.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24507404      PMCID: PMC4079766          DOI: 10.1016/j.jtcvs.2013.11.038

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

Authors: 
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

2.  Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database.

Authors:  Andrew W ElBardissi; Sary F Aranki; Shubin Sheng; Sean M O'Brien; Caprice C Greenberg; James S Gammie
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02       Impact factor: 5.209

3.  Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting.

Authors:  V H Thourani; W S Weintraub; B Stein; S S Gebhart; J M Craver; E L Jones; R A Guyton
Journal:  Ann Thorac Surg       Date:  1999-04       Impact factor: 4.330

4.  Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery.

Authors:  Jeffrey L Carson; Peter M Scholz; Anita Y Chen; Eric D Peterson; Jeffrey Gold; Stephen H Schneider
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

5.  Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors: 
Journal:  Am Heart J       Date:  2008-07-31       Impact factor: 4.749

6.  Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Maria Mori Brooks; Bernard R Chaitman; Richard W Nesto; Regina M Hardison; Frederick Feit; Bernard J Gersh; Ronald J Krone; Edward Y Sako; William J Rogers; Alan J Garber; Spencer B King; Charles J Davidson; Fumiaki Ikeno; Robert L Frye
Journal:  Circulation       Date:  2012-09-24       Impact factor: 29.690

7.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

8.  Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.

Authors:  Lauren J Kim; Spencer B King; Kenneth Kent; Maria Mori Brooks; Kevin E Kip; J Dawn Abbott; Alice K Jacobs; Charanjit Rihal; Whady A Hueb; Edwin Alderman; Ivan R Pena Sing; Michael J Attubato; Frederick Feit
Journal:  JACC Cardiovasc Interv       Date:  2009-05       Impact factor: 11.195

  8 in total
  1 in total

1.  On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Ashima Singh; Hartzell V Schaff; Maria Mori Brooks; Mark A Hlatky; Stephen R Wisniewski; Robert L Frye; Edward Y Sako
Journal:  Eur J Cardiothorac Surg       Date:  2015-05-11       Impact factor: 4.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.